UNSPSC 51291804: Nitrafudam

This classification denotes an antidepressant agent with the molecular formula C11H9N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7R3267A08Y, chemically known as 5-(2-nitrophenyl)furan-2-carboximidamide but more commonly known as nitrafudam, which bears US NIH Compound Identifier 163304. The term nitrafudam hydrochloride is a United States Adopted Name designation. European Medicines Agency schedules nitrafudam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09315MIG.

Most nations schedule nitrafudam under HS 29321900 and SITC 51569. As of Q4 2014, NITRAFUDAM remains the US FDA Preferred Term for this commodity. Nitrafudam bears US NLM identifiers UMLS ID C2983850 and NCI Concept Code C90714. SMILES: C1=CC=C(C(=C1)C2=CC=C(O2)C(=N)N)[N+](=O)[O-].

UNSPSC 51291804 Nitrafudam is a Commodity-tier code that captures pharmaceutical products procured by state and local health agencies, but the recent opportunities tagged under this code show little direct alignment with nitrafudam itself. Instead, the opportunities reveal state and local demand for naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. State and local issuing bodies soliciting pharmaceutical products under codes in this family include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work involves establishing supply agreements for pharmaceutical inventories, negotiating pricing with manufacturers and wholesalers, managing product compliance with FDA and Drug Supply Chain Security Act requirements, and organizing quarterly or ongoing deliveries to health facilities and clinics.

Recent activity spans Florida, Minnesota, and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through a competitive bid process with a response deadline of July 26, 2023, and a two-year initial term with one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, closing March 26, 2026, requiring vendors to supply through three authorized wholesalers with an effective date of July 1, 2026; evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing, and the remainder on compliance and capability factors. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs without a formal competitive deadline, seeking vendor experience with self-insured employer and state agency contracting models. Vendors must meet standard pharmaceutical compliance requirements including current Good Manufacturing Practices certification, insurance minimums of $2,000,000 to $5,000,000 depending on coverage type, and E-Verify employment verification.